Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
Top Page
VolitionRX
(NYSE MKT:VNRX)
29Underperform
Positive Factors
Global Expansion
Nu.Q Vet is now available for purchase in over 20 countries worldwide.
Licensing Opportunities
Management provided insight into growing licensing opportunities related to Nu.Q Cancer, which could be a simple and accessible routine blood test.
Product Development
The company shared data supporting Nu.Q’s utility in lung cancer screening, prognostication, monitoring, and multi-cancer applications.
Negative Factors
Commercial Partnerships
Nu.Q NETs should support the company’s ongoing discussions with potential commercial partners, highlighting reliance on future agreements.
Commercial Viability
Volition had its first commercial sale of its High Throughput Synthetic Sepsis method, indicating an early stage in commercial traction.
Market Competition
Volition is advancing several active commercial discussions with significant players in the human diagnostic and liquid biopsy space for sepsis and oncology.
VolitionRX (VNRX) vs. S&P 500 (SPY)
Market Cap
$48.37M
Dividend YieldN/A
Average Volume (3M)245.87K
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue Growth59.10%
EPS Growth37.59%
CountryUS
Employees85
SectorHealthcare
Sector Strength74
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.31
Shares Outstanding100,775,340
10 Day Avg. Volume154,677
30 Day Avg. Volume245,872
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit76.12
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.50Price Target Upside420.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
VolitionRX Business Overview & Revenue Model
Company DescriptionVolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
How the Company Makes MoneyVolitionRX generates revenue through the commercialization of its diagnostic tests, which are designed to be used in clinical settings for the early detection and monitoring of cancer and other diseases. The company earns money by licensing its technology to healthcare providers and laboratories, partnering with pharmaceutical companies for the development and distribution of its tests, and through collaborations with research institutions. Additionally, VolitionRX may receive grants and funding for research and development initiatives. The company's revenue model relies heavily on the successful validation and regulatory approval of its diagnostic tests, which can influence its ability to penetrate the healthcare market and establish partnerships.
VolitionRX Financial Statement Overview
Summary
VolitionRX faces financial difficulties with ongoing losses, high leverage, and cash flow challenges. The company needs to address profitability and liquidity issues to improve financial health and reduce reliance on external financing.Income Statement
VolitionRX shows significant challenges in profitability. Despite some revenue growth, the company maintains negative net and EBIT margins, indicating persistent losses. The TTM data reflects an increase in revenue but also a substantial net loss, highlighting ongoing financial pressure.20
Very Negative
Balance Sheet
The balance sheet displays a concerning negative stockholders' equity, indicating financial distress and high leverage. The persistently high debt-to-equity ratio underscores the company's reliance on debt financing, posing a risk to financial stability.15
Very Negative
Cash Flow
VolitionRX struggles with negative operating and free cash flows, suggesting issues with cash generation. Despite some improvement in cash flows due to financing activities, the operational cash flow remains insufficient to cover net income, highlighting liquidity concerns.25
Negative
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 775.30K | 306.39K | 90.03K | 13.43K | 17.10K | Gross Profit |
| 775.30K | -882.03K | 90.03K | 13.43K | 17.10K | EBIT |
| -35.99M | -31.78M | -28.33M | -21.25M | -16.04M | EBITDA |
| -34.04M | -29.24M | -25.69M | -19.23M | -15.07M | Net Income Common Stockholders |
| -35.32M | -30.27M | -26.97M | -20.48M | -16.03M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 20.73M | 10.87M | 20.58M | 19.44M | 16.97M | Total Assets |
| 27.95M | 18.30M | 27.49M | 26.15M | 21.29M | Total Debt |
| 5.86M | 4.97M | 4.02M | 4.44M | 3.94M | Net Debt |
| -14.87M | -5.89M | -16.56M | -15.00M | -13.03M | Total Liabilities |
| 36.66M | 21.42M | 9.77M | 9.86M | 7.09M | Stockholders Equity |
| -7.80M | -2.57M | 17.94M | 16.34M | 14.20M |
| Cash Flow | Free Cash Flow | |||
| -19.15M | -16.85M | -21.83M | -18.41M | -13.25M | Operating Cash Flow |
| -18.06M | -15.28M | -20.85M | -16.46M | -12.74M | Investing Cash Flow |
| -1.08M | -1.57M | -973.56K | -1.65M | -511.27K | Financing Cash Flow |
| 28.98M | 6.94M | 22.86M | 20.62M | 16.93M |
VolitionRX Technical Analysis
Neutral
0.48
Price Trends
0.54
Negative
0.58
Negative
0.62
Negative
Market Momentum
-0.02
Negative
46.48
Neutral
42.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VNRX, the sentiment is Neutral. The current price of 0.48 is below the 20-day moving average (MA) of 0.49, below the 50-day MA of 0.54, and below the 200-day MA of 0.62, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 46.48 is Neutral, neither overbought nor oversold. The STOCH value of 42.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VNRX.
VolitionRX Risk Analysis
VolitionRX disclosed 35 risk factors in its most recent earnings report. VolitionRX reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
VolitionRX Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $31.42M | ― | -51.22% | ― | -10.56% | 41.02% | |
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% | |
50 Neutral | $25.15M | ― | -12.94% | ― | ― | ― | |
43 Neutral | $12.37M | ― | -170.33% | ― | -14.79% | 76.94% | |
42 Neutral | $77.03M | ― | -337.30% | ― | 45.30% | 45.67% | |
42 Neutral | $9.86M | ― | -242.44% | ― | 269.68% | 17.26% | |
29 Underperform | $48.37M | ― | 138.92% | ― | 59.10% | 37.59% |
* Healthcare Sector Average
Performance Comparison
VNRX
VolitionRX
0.49
-0.39
-44.32%
ENZB
Enzo Biochem
0.49
-0.46
-48.42%
BNGO
BioNano Genomics
4.00
-52.96
-92.98%
BNR
Burning Rock Biotech
2.87
-4.72
-62.19%
BDSX
Biodesix
0.53
-0.78
-59.54%
BIAF
bioAffinity Technologies, Inc.
0.48
-1.81
-79.04%
VolitionRX Earnings Call Summary
Earnings Call Date:Mar 31, 2025
(Q4-2024)
| % Change Since: -15.79%|
Next Earnings Date:May 07, 2025
Earnings Call Sentiment Positive
VolitionRx showed significant progress in 2024 with strong revenue growth, successful cost reduction, and promising clinical advancements in both oncology and sepsis. However, challenges remain in achieving predictable revenue streams and cash flow management. The company's focus on securing multiple licensing deals in 2025 is critical to future success.Q4-2024 Updates
Positive Updates
Nu.Q Vet Cancer Test Expansion
The Nu.Q Vet Cancer Test expanded access to over 20 countries and sold approximately 120,000 tests in 2024, doubling the previous year and resulting in a 75% increase in vet revenue compared to 2023.
Significant Revenue Growth
VolitionRx recorded $1.2 million in revenue for 2024, a 59% increase from 2023. Nu.Q Vet Cancer Test revenue grew by 75%, and Nu.Q Discover revenue grew by 40%.
Cost Reduction Success
Operating expenses were reduced by 23% year-over-year, with a 31% reduction in the second half of 2024 compared to the previous year.
Nu.Q Cancer Clinical Progress
The Nu.Q Cancer platform demonstrated its ability to differentiate between malignant and benign pulmonary nodules in an 800-patient study, with further validation studies underway.
Nu.Q NETs Sepsis Marker Success
Nu.Q NETs test showed promising results across multiple studies as a surrogate marker for neutrophil extracellular traps (NETs) in sepsis, generating interest from key opinion leaders and licensing partners.
Nu.Q Discover Pharmaceutical Partnerships
VolitionRx entered into its first human clinical study partnership with a leading pharmaceutical company, expected to generate significant revenue and validate the Nu.Q Discover program.
Negative Updates
Revenue Uncertainty
Revenues remain fairly lumpy and difficult to predict quarterly, with no specific revenue guidance provided for 2025.
Cash Flow Challenges
Net cash used in operating activities was $25.9 million in 2024, although down 17% year-over-year when excluding milestone payments received in 2023.
Delayed Automation in Vet Testing
The point-of-care market for Nu.Q Vet is growing but remains less than 20% of the total market, with central lab automation crucial for accelerating growth.
Company Guidance
During the VolitionRx Limited Fourth Quarter and Full Fiscal Year 2024 Earnings Conference Call, key guidance was provided for 2025. The company aims to achieve cash neutrality, meaning that income, including licensing receipts, will match expenditures on a cash basis. In 2024, VolitionRx reported $1.2 million in revenue, a 59% increase from 2023, with Nu.Q Vet Cancer Test sales growing by 75% to $0.8 million, and Nu.Q Discover revenue rising by 40% to $0.4 million. Approximately 120,000 Nu.Q Vet cancer tests were sold, more than doubling the prior year's sales. Operating expenses were reduced by 23% year-on-year, contributing to a 17% reduction in net cash used in operating activities when excluding previous milestone payments. The company is focused on signing multiple human licensing deals in 2025, replicating its success in the veterinary space, with plans to automate centralized labs to accelerate growth and expand the use of its Nu.Q platform in clinical settings.VolitionRX Corporate Events
Private Placements and FinancingBusiness Operations and Strategy
VolitionRX Signs New Capital Sales Agreement
Neutral
Apr 22, 2025
On April 22, 2025, VolitionRx Limited entered a Capital On Demand Sales Agreement with JonesTrading Institutional Services LLC, allowing the company to sell up to $7.5 million of its common stock. This agreement replaces a prior arrangement with Jefferies LLC and aims to support VolitionRx’s research, product development, and potential strategic acquisitions. The termination of the previous agreement with Jefferies LLC, effective April 20, 2025, marks the end of the prior program, and no further sales will be made under it.
Spark’s Take on VNRX Stock
According to Spark, TipRanks’ AI Analyst, VNRX is a Underperform.
VolitionRX’s overall stock score is low due to significant financial challenges, including negative equity and cash flow issues. Technical indicators show a weak momentum, and traditional valuation metrics are unfavorable. Despite promising revenue growth and strategic initiatives highlighted in the earnings call, the company’s financial instability and execution risks weigh heavily on the stock’s outlook.
To see Spark’s full report on VNRX stock, click here.
Regulatory Filings and Compliance
VolitionRX Files New Registration Statement with SEC
Neutral
Apr 4, 2025
On April 4, 2025, VolitionRx Limited filed a New Registration Statement with the SEC to register 35,867,306 shares of its common stock, issuable upon the exercise of previously issued warrants. This move involves withdrawing these shares from a previous registration under a Shelf Registration Statement filed in 2021, streamlining the company’s regulatory filings.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.